Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploration of evolocumab lipid-lowering regimens in ASCVD
ChiCTR2200057217Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Zhengzhou University
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in atherosclerotic disease comparing Evolocumab + statins with Evolocumab + oral placebo (2 arms). Primary endpoints: Blood lipids and Carotid plaque. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2200057217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057217.